Argenx SE (ARGX) Stock: Falls Despite $1.7 Billion Sales and Profit Growth

TLDR ARGX slips 1.00% as blockbuster VYVGART sales reach $1.7 billion in Q3 2026. Argenx profit climbs to $506 million, but ARGX shares still face selling pressure. VYVGART sales jump 54% year over year as Argenx expands its treatment pipeline. Rising development costs push Argenx quarterly operating expenses to $1.27B. December empasiprubart results could mark [...]

The post Argenx SE (ARGX) Stock: Falls Despite $1.7 Billion Sales and Profit Growth appeared first on Blockonomi.